Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly...
VSee's Rapidly Configurable AI Telehealth Platform Addresses Rural Hospital Access and Financial Sustainability SAN JOSE, CALIFORNIA / ACCESS Newswire /...
Experts emphasize individualized care as demand grows for solutions to facial volume loss and loose skin following medical weight reduction....
VSee's Rapidly Configurable AI Telehealth Platform Addresses Rural Hospital Access and Financial Sustainability SAN JOSE, CALIFORNIA / ACCESS Newswire /...
Experts emphasize individualized care as demand grows for solutions to facial volume loss and loose skin following medical weight reduction....
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / For years, investors were trained to believe the bottleneck...
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / For years, investors were trained to believe the bottleneck...
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
Strategic Fit Assessment Finds Leadership Concentrated in Enterprise-Scale Clinical Performance and Resilience While Cloud Agility, Partnership Value, and Patient Engagement...
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE...
Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment in HoloTwin’s AI-driven digital twin...
DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health...
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026...
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal...
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib...
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-...
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and...
Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and...